ly-2874455
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01212107)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CC(Oc1ccc2[nH]nc(/C=C/c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl- Mol. weight
- 444.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3828009 ↗
- ChEMBLCHEMBL3545264 ↗
Also known as
- 2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3yl)vinyl)-1h-pyrazol-1-yl)ethanol
- ly2874455
- ly2874455
- ly2874455
- ly-2874455
- ly-2874455
- ly-2874455
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03125239 | Phase 1 | May 1, 2017 | Eli Lilly, Harvard University |
| NCT01212107 | Phase 1 | Dec 1, 2010 | Eli Lilly |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 1 | 1 | 2010 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1